Latest Feature

Gov. Deval Patrick's life sciences legacy

MassDevice.com looks at the life sciences legacy of former Massachusetts Gov. Deval Patrick.

Weight loss: ReShape Medical's Duo balloon system looks to curb obesity

A Q&A with ReShape Medical CEO Richard Thompson on the company's cash pay procedure and how it can make a dent in obese patients.

DeviceTalks podcast: Masimo CEO Kiani

An interview with medtech entrepreneur Joe Kiani, CEO of Masimo Corp. and the founder of the Patient Safety Movement Foundation, recorded at DeviceTalks West Nov. 19, 2014.

HeartFlow wins FDA OK for non-invasive FFR system

The FDA grants de novo clearance to HeartFlow's novel system for non-invasive measurement of fractional flow reserve, which CEO Dr. John Stevens calls "the gold standard" for diagnosing and treating coronary disease.

DeviceTalks podcast: B. Braun Medical CEO Caroll Neubauer on device tax, Obamaca

Caroll Neubauer, the CEO of B. Braun Medical, sits down for a wide-ranging interview on the hottest topics facing the medical device industry.

Latest Jobs

Knowledge Library

This manual contains valuable information about working with silicone vs. thermoplastics, silicone use for medical applications, choosing the right silicone
Subscribe to the MassDevice
Newsletter
Enter your email:

Need Medtech news in a minute? We Deliver!


MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter.

Study: DAPT duration after drug-eluting stent surgery unclear

May 26, 2015 by Fink Densford

A new study of patients treated with long-duration dual-antiplatelet therapies after the placement of drug-eluting stents shows a lower rate of heart attack but a higher risk for major bleeding events.

DAPT duration after drug-eluting stent surgery unclear

Patients treated with long-duration anti-platelet therapies after the placement of a drug-eluting stent showed lower rates of heart attack but higher rates of major bleeding events and a slight increase in mortality, according to a new study released today.

MassDevice.com +3 | The top 3 medtech stories for May 26, 2015

May 26, 2015 by MassDevice

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

 

Medtech trio sets $297m offering terms

May 26, 2015 by Brad Perriello

A trio of medical device companies - Evolent Health, EndoChoice and Corindus Vascular Robotics - sets terms for public offerings today that could bring in a collective $297 million.

IPO Tuesday: Medtech trio sets offering terms

A trio of medtech companies set terms for their upcoming public offerings today, announcing plans to raise a collective $297 million.

Sorin shareholders OK Cyberonics Merger

May 26, 2015 by Fink Densford

Sorin's shareholders approve the Italian medical device firm's merger with U.S.-based Cyberonics.

Sorin shareholders OK Cyberonics Merger

Another halt for St. Jude Medical's European Nanostim trial

May 26, 2015 by Brad Perriello

St. Jude Medical calls another halt to its Nanostim clinical trial in Europe after serious adverse events surfaced in several patients.

Another halt for St. Jude Medical's Nanostim trial

Medtech engineer starts high-tech wine company Coravin

May 26, 2015 by Fink Densford

Intrinsic Therapeutics' founder George Lambrecht starts Coravin, a high-tech wine device company that allows for untapped wine access.

Medtech engineer starts high-tech wine company Coravin

Medtech engineer and founder of Intrinsic Therapeutics George Lambrecht has formed Coravin, a high-tech wine company that produces a device for tapping wine bottles without removing the cork.

Life sciences challenge tech in global innovation

May 26, 2015 by MassDevice

The life sciences industry is increasingly taking over from the tech sector in driving global innovation.

Life sciences challenge tech in global innovation

(Reuters) — The life sciences industry is increasingly taking over from the tech sector in driving global innovation, according to a Thomson Reuters analysis of global patents.